Antiviral drug discovery: preparing for the next pandemic
Chemical Society Reviews2021Vol. 50(6), pp. 3647–3655
Citations Over TimeTop 10% of 2021 papers
Catherine S. Adamson, Kelly Chibale, Rebecca J. M. Goss, Marcel Jaspars, David Newman, Rosemary A. Dorrington
Abstract
Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts.
Related Papers
- Antiviral drug treatment for emerging swine flu.(2009)
- → Advances in Antiviral Drug Discovery and Development: Part I: Advancements in Antiviral Drug Discovery(2009)14 cited
- Short-term and long-term efficacy of antiviral treatment of patients with HBV-associated acute-on-chronic liver failure(2013)
- → Comparison of fibrosis-adjusted long-term clinical outcomes in patients with minimally active chronic hepatitis B who did not undergo antiviral therapy vs. those with complete virological response by antiviral therapy(2018)
- → Erratum to: Effects of antiviral therapy on long‐term outcome after liver resection for hepatitis B virus‐related hepatocellular carcinoma(2012)